LAPTM4B polymorphisms is associated with ovarian cancer susceptibility and its prognosis

Japanese Journal of Clinical Oncology

Volumn 42, Issue 5, 2012, Pages 413-419

  Xu, Ye ^a   Liu, Yunduo ^a   Zhou, Rouli ^b   Meng, Fanling ^a   Gao, Ying ^a   Yang, Shanshan ^a   Li, Xueting ^a   Yang, Meng ^a   Lou, Ge ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

LAPTM4B; Ovarian cancer; Polymorphism; Prognosis; Susceptibility

Indexed keywords

GENOMIC DNA; LYSOSOME ASSOCIATED PROTEIN TRANSMEMBRANE 4 BETA PROTEIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LYMPHOCYTE; MAJOR CLINICAL STUDY; OVARY CANCER; POLYMERASE CHAIN REACTION; PROGNOSIS;

ADENOCARCINOMA; ADULT; AGED; ALLELES; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, MUCINOUS; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM GRADING; ONCOGENE PROTEINS; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS;

EID: 84860489042     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys026     Document Type: Article

References (25)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics. CA Cancer J Clin 2005;55:10-30.
2. Liu XR, Zhou RL, Zhang QY, Zhang Y, Jin YY, Lin M, et al. Structure analysis and expressions of a novel tetratransmembrane protein, lysosoma associated protein transmembrane 4 beta associated with hepatocellular carcinoma. World J Gastroenterol 2004;10:1555-9.
3. Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, Rui JA, et al. Molecular cloning and characterization of LAPTM4B, a novel gene upregulated expressed in hepatocellular carcinoma. Oncogene 2003;22:5060-9.
4. Liu J, Zhou R, Zhang N, Rui J, Jin C. Biological function of a novel gene overexpressed in human hepatocellular carcinoma. Chin Med J (Engl) 2000;113:881-5.
5. Peng C, Zhou RL, Shao GZ, Rui JA, Wang SB, Lin M, et al. Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma. World J Gastroenterol 2005;11:2704-8.
6. Liu X, Zhou R, Zhang Q, Zhang Y, Shao G, Jin Y, et al. Identification and characterization of LAPTM4B encoded by a human hepatocellular carcinoma-associated novel gene. Beijing Da Xue Xue Bao 2003;35:340-7.
7. Li C, Zhou Q, Wang Y, Chen X, Yang X, Zhu D. Relationship between LAPTM4B gene polymorphism and susceptibility of lung cancer. Chin J Lung Cancer 2006;9:109-12.
8. Zhou L, He XD, Chen J, Cui QC, Qu Q, Rui JA, et al. Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma. Eur J Cancer 2007;43:809-15.
9. Meng F, Luo C, Hu Y, Yin M, Lin M, Lou G, et al. Overexpression of LAPTM4B-35 in cervical carcinoma: a clinicopathologic study. Int J Gynecol Pathol 2010;29:587-93.
10. Meng FL, Yin MZ, Song HT, Yang H, Lou G, Zhou RL. LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma. Int J Gynecol Cancer 2010;20:745-50.
11. Yin M, Xu Y, Lou G, Hou Y, Meng F, Zhang H, et al. LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis. Int J Cancer 2011;129:629-35.
12. Meng F, Song H, Luo C, Yin M, Xu Y, Liu H, et al. Correlation of LAPTM4B polymorphisms with cervical carcinoma. Cancer 2011;117:2652-8.
13. Scully R. Histological Typing of Ovarian Tumors (WHO. World Health Organization. International Histological Classification of Tumours). Berlin: Springer 1999.
14. Benedet JL, Bender H, Jones H, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000;70:209-62.
15. Stern C. The Hardy-Weinberg law. Science 1943;97:137-8.
16. Taningher M, Malacarne D, Izzotti A, Ugolini D, Parodi S. Drug metabolism polymorphisms as modulators of cancer susceptibility. Mutation Res 1999;436:227-61.
17. Mohrenweiser H, Jones IM. Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation. Mutation Res 1998;400: 15-24.
18. Deng LJ, Zhang QY, Liu B, Zhou RL. Relationship between LAPTM4B gene polymorphism and susceptibility of lung cancer. Beijing Da Xue Xue Bao 2005;37:302-5.
19. Liu Y, Zhang QY, Qian N, Zhou RL. Relationship between LAPTM4B gene polymorphism and susceptibility of gastric cancer. Ann Oncol 2007;18:311-6.
20. Cabrita MA, Hobman TC, Hogue DL, King KM, Cass CE. Mouse transporter protein, a membrane protein that regulates cellular multidrug resistance, is localized to lysosomes. Cancer Res 1999;59:4890-7.
21. Hogue DL, Nash C, Ling V, Hobman TC. Lysosome-associated protein transmembrane-4 alpha (LAPTM4 alpha) requires two tandemly arranged tyrosine-based signals for sorting to lysosomes. Biochem J 2002;365:721-30.
22. Hunziker W, Geuze HJ. Intracellular trafficking of lysosomal membrane proteins. Bioessays 1996;18:379-89.
23. Hogue DL, Kerby L, Ling V. A mammalian lysosomal membrane protein confers multidrug resistance upon expression in Saccharomyces cerevisiae. J Biol Chem 1999;274:12877-82.
24. Hogue DL, Ellison MJ, Young JD, Cass CE. Identification of a novel membrane transporter associated with intracecellular membranes by phenotypic complementation in the yeast Saccharomyces cerevisiae. J Biol Chem 1996;271:9801-8.
25. Xinrong Liu, Fuxia Xiong, Xuanhui Wei, Hua Yang, Rouli Zhou. LAPTM4B-35, a noval tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells. Cancer Science 2009;100: 2335-40.